5

Preoperative Anti-VEGF Therapy May Reduce Postoperative Macular Edema in Eyes With Retinal Vein Occlusion

Publication date: October 16, 2026
Source: Primary Care Optometry News /
Study publication: BMC Ophthalmology; full citation and DOI not provided in the supplied report

1-Minute Summary

Anti–vascular endothelial growth factor (anti-VEGF) treatment administered shortly before cataract surgery may be associated with a lower risk of postoperative macular edema in patients with retinal vein occlusion (RVO), according to a retrospective study reported in BMC Ophthalmology.

The analysis included 53 eyes from 51 patients with central or branch RVO who subsequently underwent cataract surgery. Among eyes previously treated with anti-VEGF, postoperative macular edema occurred in 12.5% of eyes when the most recent injection was given within 35 days before surgery, compared with 57.1% when treatment occurred more than 35 days before surgery.

Across the entire cohort, 26.1% of eyes developed postoperative macular edema, with onset occurring an average of 48.1 days after surgery. Recent anti-VEGF treatment remained the only statistically significant factor associated with postoperative macular edema in a multivariable analysis adjusted for ischemic status and diabetes.

These findings suggest that the timing of anti-VEGF therapy may matter when planning cataract surgery for patients with RVO. However, the small, retrospective study cannot establish that preoperative injections directly prevent postoperative edema or determine the optimal timing of treatment.

Why This Matters

Retinal vein occlusion can impair retinal blood flow and increase vascular permeability, contributing to macular edema and reduced visual function. Cataract extraction may improve vision in affected patients, but surgery can also increase the risk of postoperative macular edema, particularly in eyes with preexisting retinal vascular disease.

The investigators noted that patients with RVO and concurrent cataract can experience meaningful visual improvement after cataract extraction. However, they also emphasized that surgery presents a challenge because of the increased risk of postoperative macular edema.

The study raises a clinically relevant question: Could administering anti-VEGF therapy closer to cataract surgery help reduce this complication?

The findings suggest a possible benefit when treatment is administered within 35 days before surgery. If confirmed in larger prospective studies, this approach could inform preoperative assessment, treatment timing, and postoperative monitoring. It should not yet be interpreted as a universal requirement for all patients with RVO undergoing cataract surgery.

Study at a Glance

What the Researchers Found

1. Recent anti-VEGF treatment was associated with a lower frequency of postoperative macular edema

The researchers retrospectively evaluated 53 eyes from 51 patients diagnosed with central or branch RVO who subsequently underwent cataract surgery in the affected eye.

Of the 53 eyes, 38 had received anti-VEGF treatment before surgery, whereas 15 had never received anti-VEGF therapy. Among previously treated eyes, the investigators examined whether the most recent injection had been administered within 35 days of surgery or more than 35 days beforehand.

The frequency of postoperative macular edema was substantially lower among eyes receiving anti-VEGF treatment within the 35-day window.

The difference suggests that a more recent injection may be associated with better control of postoperative retinal fluid accumulation. Nevertheless, the supplied report does not provide the subgroup denominators, confidence intervals, or exact P value for this comparison. The percentages should therefore be interpreted as descriptive study findings rather than precise estimates of treatment effect.

2. Previous exposure alone did not appear to provide lasting protection

When the investigators compared eyes that had received anti-VEGF treatment at any time in the past with eyes that had never received it, the reported postoperative macular edema rates were similar.

The results did not suggest a lower edema rate simply because an eye had received anti-VEGF therapy at some point in the past.

The investigators proposed that long-term prior exposure may not provide durable protection against the postoperative complication. Instead, the timing of the most recent treatment may be more relevant.

These comparisons should be interpreted cautiously: the treatment groups may have differed in disease severity, activity, or other clinical characteristics, and the small sample limits the ability to establish meaningful differences.

3. Findings in ischemic RVO suggested a potentially important timing effect

Among eyes with ischemic RVO, no postoperative macular edema was reported in the subgroup receiving anti-VEGF treatment within 35 days before surgery. By comparison, postoperative macular edema occurred in 80% of eyes whose most recent injection was administered more than 35 days before surgery.

Although this contrast is striking, the subgroup sample sizes were not provided in the source report. A zero-event finding in a small subgroup does not establish that treatment eliminates risk. Larger studies are needed to determine whether the apparent association is reproducible and whether it differs by RVO subtype or ischemic status.

4. Recent treatment remained significant after adjustment

The investigators conducted a multivariable analysis that adjusted for ischemic status and diabetes. According to the report, recent anti-VEGF treatment remained the only statistically significant factor associated with the odds of postoperative macular edema.

This finding suggests that the association was not fully explained by those two measured factors. However, statistical adjustment cannot eliminate all potential confounding, particularly in a small retrospective cohort. The supplied report does not include the adjusted odds ratio, confidence interval, or P value, limiting assessment of the magnitude and precision of the association.

5. Postoperative macular edema remained relatively common

Across the full cohort, 26.1% of eyes developed postoperative macular edema. The average time to its development was 48.1 days after cataract surgery.

The investigators characterized this as a high incidence of postoperative edema in eyes with RVO, regardless of the apparent level of disease activity.

They suggested that preoperative treatment might be beneficial even in patients whose RVO appears inactive. That interpretation is hypothesis-generating, however, and should not be treated as a definitive recommendation to administer anti-VEGF therapy to every patient with a history of RVO.

What the Investigators Said

The investigators emphasized the competing clinical considerations associated with cataract surgery in patients with retinal vein occlusion:

“Patients with [retinal vein occlusion] and concurrent cataract have been shown to benefit from cataract extraction to significantly improve visual outcomes.”

They also noted:

“However, [cataract extraction] poses challenges, as it significantly increases the risk of postoperative macular edema in patients with preexisting [retinal vein occlusion].”

Regarding a possible biological explanation, the researchers proposed that anti-VEGF therapy may:

“ameliorates the vascular permeability”

underlying postoperative macular edema in these patients.

The report also highlighted the potential limitations of remote treatment, suggesting that:

“any long-term prior anti-VEGF exposure does not grant durable protection against postoperative macular edema.”

The investigators concluded that the high frequency of edema could support considering pretreatment across different levels of prior disease activity, while further research is needed to clarify which patients are most likely to benefit.

Clinical Significance

The findings point to the potential importance of coordinating retinal treatment and cataract surgery in patients with RVO. Anti-VEGF therapy is used to reduce abnormal vascular permeability in retinal disease, and a recent injection may help control edema during the perioperative period. The present study, however, demonstrates an association rather than proof of a preventive effect.

For clinicians, the main consideration is not simply whether a patient has previously received anti-VEGF treatment, but whether the patient’s retinal condition and treatment schedule warrant reassessment before surgery.

The results may support discussion between the cataract surgeon and the clinician managing the RVO. Decisions should be individualized according to the patient’s retinal findings, disease history, prior treatment response, visual needs, and surgical plan.

The study does not establish that 35 days is a definitive treatment cutoff. Nor does it determine whether an additional injection is necessary, what dose or agent should be used, or whether treatment timing should differ between central and branch RVO.

Perspective: Practical Considerations Before Cataract Surgery

Robert Bittner, OD, FAAO, of the University of Pittsburgh, emphasized the importance of identifying a history of RVO when assessing cataract surgery candidates.

He recommended that clinicians communicate this history to the cataract surgeon so that the team can consider whether preoperative anti-VEGF therapy is appropriate. His perspective also emphasized obtaining a thorough ocular history, especially when patients may not reliably recall previous retinal disease or treatment.

Bittner suggested that clinicians consider obtaining baseline optical coherence tomography (OCT) of the macula before cataract surgery. OCT may help identify macular changes consistent with prior RVO or other pathology that is not readily apparent during a routine clinical examination.

These recommendations represent clinical perspective accompanying the news report, rather than a formal guideline established by the study.

What Doctors Should Know

• Ask about prior RVO: Document whether the patient has a history of central or branch RVO, including previous retinal treatment and episodes of macular edema.
• Assess current macular status: Consider preoperative retinal evaluation and macular OCT when clinically appropriate, especially when prior retinal disease or residual edema is suspected.
• Coordinate care: Communicate with the clinician managing the RVO to discuss disease activity, previous response to anti-VEGF therapy, and the timing of the last injection.
• Consider timing individually: The study found a lower edema frequency when the most recent injection occurred within 35 days before surgery, but it did not establish a universal treatment window.
• Plan postoperative surveillance: Because edema developed an average of 48.1 days after surgery in this cohort, postoperative monitoring should account for the possibility of delayed macular complications. The study does not establish a specific follow-up schedule.
• Avoid overinterpreting subgroup results: The reported 0% vs 80% contrast in ischemic RVO is based on subgroup data whose denominators were not supplied.
• Explain the uncertainty: Patients should understand that the findings are preliminary and do not prove that preoperative anti-VEGF therapy will prevent edema.

Limitations

Several limitations affect the interpretation and generalizability of the findings.

1. Retrospective design: Treatment timing was not randomly assigned. Differences between patients who received recent and remote injections may have influenced outcomes.
2. Small sample: The study included only 53 eyes from 51 patients. This limits statistical precision and makes subgroup findings particularly vulnerable to instability.
3. Potential confounding: The adjusted analysis accounted for ischemic status and diabetes, but other factors may have affected postoperative edema risk. These could include baseline macular status, RVO duration, prior edema severity, anti-VEGF agent, treatment frequency, and surgical factors; the supplied report does not specify how these variables were handled.
4. Incomplete statistical reporting in the news article: The report does not provide subgroup denominators, adjusted effect estimates, confidence intervals, or exact P values. The magnitude and precision of the association therefore cannot be fully evaluated from the supplied information.
5. Unspecified follow-up duration: The full observation period and the criteria used to diagnose postoperative macular edema are not described in the supplied report.
6. Limited ability to establish causality: The observed association does not prove that recent anti-VEGF therapy caused the lower edema frequency. Prospective studies, ideally with well-defined treatment protocols and appropriate comparison groups, are needed.
7. Uncertain generalizability: The results may not apply equally to all patients with RVO, all anti-VEGF agents, or all cataract surgery settings.

Original Research / DOI

The report identifies BMC Ophthalmology as the publication venue but does not provide the original article title, complete author list, publication date, volume, article number, or DOI.

Original research citation: Not fully available in the supplied source. The article should be identified and verified through the journal or PubMed before adding a formal reference or DOI to the published version.

Evidence classification: Retrospective observational study, as described in the report. This is not a randomized controlled trial, and the findings should not be described as definitive proof that preoperative anti-VEGF treatment prevents postoperative macular edema.

Bottom Line

In a small retrospective cohort of patients with retinal vein occlusion undergoing cataract surgery, postoperative macular edema was less frequent when the most recent anti-VEGF injection was administered within 35 days before surgery than when treatment occurred more than 35 days beforehand. Overall, approximately one-quarter of eyes developed postoperative macular edema, with onset occurring about 7 weeks after surgery on average.

The findings suggest that recent anti-VEGF treatment may be relevant to perioperative planning, but they do not establish a causal protective effect or a universal injection schedule. A careful ocular history, appropriate preoperative macular assessment, coordination between retinal and cataract clinicians, and individualized postoperative monitoring remain important.